skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

The use of sibutramine in the management of obesity and related disorders: An update

Review

(3145) Views  (1012) Full article downloads

Authors: Konstantinos Tziomalos, Gerasimos E Krassas, Themistoklis Tzotzas

Published Date May 2009 Volume 2009:5 Pages 441 - 452
DOI: http://dx.doi.org/10.2147/VHRM.S4027

Konstantinos Tziomalos, Gerasimos E Krassas, Themistoklis Tzotzas

Department of Endocrinology, Diabetes and Metabolism, Panagia General Hospital, Thessaloniki, Greece

Aims: To review the major trials that evaluated the efficacy and safety of the use of sibutramine for weight loss and the impact of this agent on obesity-related disorders.

Methods and results: The most important articles on sibutramine up to January 2009 were located by a PubMed and Medline search. Sibutramine reduces food intake and body weight more than placebo and has positive effects on the lipid profile (mainly triglycerides and high density lipoprotein cholesterol), glycemic control and inflammatory markers in studies for up to one year. Preliminary studies showed that sibutramine may also improve other obesity-associated disorders such as polycystic ovary syndrome, left ventricular hypertrophy, binge eating disorder and adolescent obesity. The high discontinuation rates and some safety issues mainly due to the increase in blood pressure and pulse rate have to be considered. Additionally, it has not yet been established that treatment with sibutramine will reduce cardiovascular events and total mortality.

Conclusions: Sibutramine, in conjunction with lifestyle measures, is a useful drug for reducing body weight and improving associated cardiometabolic risk factors and obesity-related disorders. Studies of longer duration are required to determine the precise indications of the drug, to evaluate safety issues and to assess its efficacy on cardiovascular mortality.

Keywords: Sibutramine, obesity, weight loss, cardiometabolic risk factors, obesity-related disorders, side-effects








Readers of this article also read:

Risk stratification for arrhythmic death in an emergency department cohort: a new method of nonlinear PD2i analysis of the ECG
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
The pathophysiology of bronchiectasis
Coenzyme Q10 effects in neurodegenerative disease
Cough and asthma diagnosis: physicians’ diagnosis and treatment of patients complaining of acute, subacute and chronic cough in rural areas of Japan
The dual kinase complex FAK-Src as a promising therapeutic target in cancer
Tiotropium bromide inhibits TGF-ß-induced MMP production from lung fibroblasts by interfering with Smad and MAPK pathways in vitro
Detection of retinal changes in Parkinson's disease with spectral-domain optical coherence tomography
Low intracellular ATP levels exacerbate carcinogen-induced inflammatory stress response and inhibit in vitro tubulogenesis in human brain endothelial cells
Phenotype characterization of embryoid body structures generated by a crystal comet effect tail in an intercellular cancer collision scenario
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University